Canopy Growth shares fall 2.22% intraday after Trump's comments on marijuana reclassification and Q1 earnings report.
ByAinvest
Tuesday, Aug 12, 2025 10:30 am ET1min read
CGC--
Canopy Growth Corporation fell 2.22% intraday, following Trump's consideration to reclassify cannabis as a Schedule III drug, which could change industry tax regulations and encourage investment. The company also reported a 9% year-over-year increase in revenue for the first quarter of fiscal 2026, with adult-use cannabis revenue in Canada rising 43%. Additionally, the company recently reduced $50M in loan debt, expecting to save $6.5M in annual interest costs.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet